Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro by Ren, Liqun et al.
ORIGINAL INVESTIGATION Open Access
Vasculoprotective effects of rosiglitazone through
modulating renin-angiotensin system in vivo and
vitro
Liqun Ren
*, Naifeng Liu, Hong Zhi, Yingjuan Li, Yanzhi Li, Rining Tang, Zulong Sheng
Abstract
Background: The peroxisome proliferator-activated receptor-g (PPARg) agonist rosiglitazone has been suggested to
exert cardiovascular protection through the improvement of lipid metabolism, anti-inflammation, anti-proliferation
etc. However, whether renin-angiotensin system (RAS) is involved in the vascular protective effects of PPARg
agonists is not fully understood. The present study aimed to investigate the effects of the renin-angiotensin system
in vascular protection mediated by PPARg agonists.
Objective: To investigate the actions of the renin-angiotensin system in vascular protection mediated by activation
of PPARg in vivo and in vitro.
Methods: Rats were fed a regular diet (n = 8), a cholesterol-rich diet plus methylthiouracil (80 mg/Kg/day, n = 10),
a cholesterol-rich diet plus methylthiouracil and rosiglitazone (4 mg/kg/day, n = 10). The rosiglitazone treatment
was started from one month after the start of cholesterol-rich diet plus methylthiouracil, and lasted five months.
Cultured vascular smooth muscle cells (VSMCs) were pretreated with 1 μmol/L angiotensin II (ANG II) for 6 h and
randomly divided into the control group; the ANG II group (1 μmol/L ANG II); the groups respectively treated with
different concentration rosiglitazone (20, 30, 50) μmol/L for 12 h; the groups treated with 30 μmol/L rosiglitazone
for (6, 12, 24) h. Morphology changes of the aortic tissues were observed by hematoxylin and eosin stain. The
VSMC growth was detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric
assay. Angiotensin II and expression of angiotensin receptors were determined by radioimmunoassay, reverse
transcription polymerase chain reaction (RT-PCR), western blot, and immunohistochemistry.
Results: After 6 months, lipid deposition, VSMC proliferation and migration toward intima were observed in aortic
tissues in the rats on a cholesterol-rich diet plus methylthiouracil, while these pathological changes induced by the
cholesterol-rich diet were significantly suppressed by rosiglitazone. In addition, VSMC proliferation induced by ANG
II was markedly inhibited by rosiglitazone. Rosiglitazone markedly down-regulated expression of angiotensin type 1
receptor (AT1R) and up-regulated expression of angiotensin type 2 receptor (AT2R) in the aortic tissues and ANG II-
treated VSMCs.
Conclusions: The present study demonstrated that PPARg agonist rosiglitazone suppressed ANG II-induced VSMC
proliferation in vitro and early atherosclerotic formation evoked by cholesterol-rich diet in vivo. These
vasculoprotective effects of rosiglitazone were mediated at least partially by reduction in local tissue ANG II
concentration, down-regulation of AT1R expression and up-regulation of AT2R expression both at the mRNA and
protein levels.
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Although meta-analyses on rosiglitazone have raised some
concerns in its clinical use, there are no outcomes data to
support these concerns. Peroxisome proliferator-activated
receptor-g (PPARg), a member of the nuclear receptor
superfamily of ligand-activated transcription factors, is a
key regulator of adipogenesis and lipid metabolism [1].
Besides their well-recognized insulin-sensitizing property,
synthetic PPAR-g agonists, such as rosiglitazone, have
been shown to possess strong anti-inflammatory proper-
ties [2]. In vitro, PPARg agonist reduces intercellular adhe-
sion molecule-1 (ICAM-1) expression in activated
endothelial cells, inhibits production of proinflammatory
cytokines (TNF-a, IL-6, and IL-1b) by activated mono-
cytes, decreases transcription of monocyte chemoattrac-
tant protein, and significantly reduces monocyte/
macrophage homing to atherosclerotic plaques [3-5]. In
several studies, it has been demonstrated that treatment
with PPARg agonists markedly reduces MI/reperfusion
injury in vivo, cardiac hypertrophy, and atherosclerotic
lesion formation through anti- inflammatory effects [6-10].
Considerable evidence obtained from animal studies as
well as clinical observations has demonstrated that
hypercholesterolemia is an independent risk factor for cor-
onary artery disease. Previous studies have also demon-
strated that hypercholesterolemia is associated with an
increased inflammatory response [11]. Moreover, hyperch-
olesterolemia activates renin-angiotensin system (RAS) and
accelerates atherosclerotic lesion formation [12]. Angioten-
sin II receptors have two main types that are called angio-
tensin II type 1 receptor (AT1R) and angiotensin II type 2
receptor (AT2R). Hypercholesterolemia increases AT1
receptor density and functional responsiveness [13,14].
More convincingly, atherosclerosis prone male apolipopro-
tein E (apoE) deficient mice that also lack the AT1A recep-
tor (double knock out) exhibit reduced atherosclerosis
compared with wild type apoE KO mice [15]. However,
the interactions between the PPARg activation and the
RAS, which may have contributed to vascular protection
against hypercholesterolemia, have not been previously
defined. In addition, the role of the AT2 receptor in diet-
induced hypercholesterolemia has been unknown.
Therefore, the aims of the present study were to
investigate whether PPARg ligand agonists exert vascular
protective effects through the modulation of the RAS
components, and if so, how–with particular regard to
changes in angiotensin II receptor expression in the
hypercholesterolemic rat model.
Materials and methods
In vivo studies
All procedures involving animals complied with national
guidelines and were approved by the regional ethical
committee. Male Wistar-Kyoto rats weighing 150-190 g
and obtained from a professional provider (Si Lai Ke
Experimental Animal Co. Ltd., Shanghai) were housed
in a room with temperature maintained at 22°C and a
light-controlled 12 h light/dark cycle. Water and food
were freely available throughout the experiment.
Twenty-eight rats were randomly allocated into one of
the following groups: (1) the control group (Con group,
n = 8), which was fed a regular diet; (2) the cholesterol-
rich diet group (Cho group, n = 10), which was fed a
cholesterol-rich diet plus methylthiouracil (80 mg/Kg/
day); (3) the rosiglitazone group (Ros group, n = 10),
which was fed a cholesterol-rich diet plus methylthiour-
acil and rosiglitazone (4 mg/kg/day; Shanghai Sunve
Pharmaceutical Co. Ltd., China). The cholesterol-rich
diet contained 10% lard, 4% cholesterol, 0.5% tauro-
cholic acid, and 85.5% regular chow. Rosiglitazone or
methylthiouracil was dissolved in 1 mL physiological sal-
ine and administrated once a day by gavages. The rosi-
glitazone treatment was started from one month after
the start of cholesterol-rich diet plus methylthiouracil,
and lasted five months.
Morphology and immunohistochemistry
For each rat on three sections chosen from the aortic sam-
ple we performed hematoxylin and eosin (HE) staining
and assessed aortic morphology changes. The vascular
trees were isolated and perfused with phosphate-buffered
solution (PBS) to clear the lumen of blood, followed by
fixation with 4% paraformaldehyde for 5-10 min. The
thoracic aorta was cleared from surrounding fat and tissue,
and dissected along the long axis. Evaluation of athero-
sclerotic lesions was performed from longitudinal sections
of aortic arches. A 3 mm long segment of the proximal
aorta was fixed with 4% paraformaldehyde for 5 - 10 min
and embedded in paraffin for later evaluation of lesion size
(intima and media) and immunohistochemistry assays.
The 4 μm thick serial sections were prepared and stained
with HE for light microscopic evaluation. The lipid deposi-
tion in atherosclerotic lesions was visualized by oil red O
staining as described previously [16]. The rest of the aorta
was stored at -80°C for RT-PCR and western blot analysis
of angiotensin II receptors, and for measurement of angio-
tensin II (ANG II).
Three sections chosen from aortic sample of per rat
were performed immunohistochemical analysis for the
expression of AT1Ra n dA T 2R. Immunostaining was
performed using the avidin-biotin complex (ABC)
method with horserasish peroxidase (HRP)-conjugated
secondary antibodies and diaminobenzidine (DAB) as
substrate. Briefly, 4 μm thick slides were dewaxed, rehy-
drated, air-dried, and blocked with blocking solution
(H -1009, Sigma, USA). The sections were incubated at
4°C overnight with goat anti-rat AT1Ro rA T 2Rp o l y -
clonal antibody (cat no. sc-31181 and sc-48451,
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diluted 1:100 in 5% serum in PBS. Thereafter, the slides
were incubated at room temperature for 90 min with an
HRP-conjugated donkey anti-goat secondary antibody
(AP180P; Pierce Biotechnology, USA) diluted 1:100 in
5% serum in PBS. Secondary antibody was detected with
the ABC kit vectastain and DAB reagent (Vector
Laboratories, inc.). Negative controls were run using an
identical protocol but excluding the primary antibody.
Morphological differences were independently assessed
in a blind fashion by two individuals who examined the
same slides. Immunohistochemical analysis was per-
formed using Olympus Micro Image analysis software
(version 4.0; Olympus Optical, Japan). The positive
staining areas were automatically traced. The total opti-
cal density (OD) was calculated using the following for-
mula: OD = (1/red intensity + 1/blue intensity + 1/
green intensity) × area of positive staining.
In vitro studies
Vascular smooth muscle cells (VSMCs) were isolated
from aortic media of four-week-old male Sprague-Dawley
rats by enzymatic digestion and cultured in monolayer.
Cultured VSMCs were confirmed by electron microscopy
and immunocytochemical staining. VSMCs in passage
4 ~ 8 in log phase were used in following experiments.
VSMCs were pretreated with 1 μmol/L ANG II for 6 h
and randomly divided into the following groups: the con-
trol group (10% fetal bovine serum in Dulbecco’sM o d i -
fied Eagle Medium); the ANG II group (1 μmol/L ANG
II); the groups respectively treated with different concen-
tration rosiglitazone (20, 30, 50) μmol/L for 12 h; the
groups respectively treated with 30 μmol/L rosiglitazone
for (6, 12, 24) h. The VSMC growth was assessed by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) colorimetric assay. mRNA and protein
expression of angiotensin II receptors in all groups were
detected by reverse transcription polymerase chain reac-
tion (RT-PCR) and western blot, respectively.
Biochemical analysis
Fasting serum lipid concentrations were determined
using the cholesterol esterase/peroxidase enzymatic
method for total cholesterol (TC), the lipase glycerol
kinase enzymatic method for total triglycerides (TG),
and the homogeneous assay for low-density lipoprotein
cholesterol (LDL-C), as described in detail elsewhere
and recommended by the National Cholesterol Educa-
tion Program (NCEP), USA [17,18].
Measurements of angiotensin II in plasma and aortic
tissues
Prior to sacrifice of the Wistar-Kyoto rats at the end of
6 months of diet blood samples were taken by puncture
of the left ventricular cavity. Aortic tissue was cut into
tiny pieces and boiled for 15 min in 0.2 mol/L glacial
acetic acid at the following ratio of tissue weight (g) to
volume of glacial acetic acid (mL): 15:1. The homoge-
nates of aortic tissue were centrifuged at 10,000 rpm for
15 min, at 4°C. Segregated supernatant fluid and plasma
were frozen at -80°C for later measurement of ANG II
concentration using radioimmunoassay (Beijing Atomic
Hi-Tech Co., Ltd, China). Total protein in supernatant
fluid was measured using the Coomassie Brilliant Blue
method as described previously [19]. ANG II concentra-
tion in the tissues (ng per mg tissue) was calculated
according to the formula: ANG II concentration
(ng/mg) = ANG II in the supernatant fluid (ng/mL)/
total protein in the supernatant fluid (mg/mL).
Quantification of gene expression
Total RNA from the thoracic aorta or treated VSMCs
was extracted using Trizol Reagent (Roche; Nanjing
Bofei Biotechnology Co. Ltd, China), followed by reverse
transcription according to the manufacturer’sp r o t o c o l .
RT-PCR was performed according to standard proce-
dures, with 35 cycles of amplification using primer
sequences as follows: AT1Rs e n s e5 ’- CTA CCG CCC
TTC AGA TAA CA - 3’ and antisense 5’- CCA AAT
CCA TAC AGC CAC TC-3’ (a 352-bp fragment); AT2R
sense 5’- GGA CCT GTG ATG TGC AAA GT - 3’ and
antisense 5’- CAC GGG TAA TTC TGT TCT TC-3’ (a
418-bp fragment). ß-actin (232-bp fragment) was
selected as reference gene. Each run contained an inter-
nal control. The PCR reaction was carried out in stan-
dard buffer (TaKaRa Biotechnology Co. Ltd, Dalian,
China). One-step RT-PCR conditions were as follows:
AT1R :1m i na t9 4 ° C ,4 5s e c o n d sa t5 8 ° C ,1m i na t
72°C; AT2R :3m i na t9 4 ° C ,4 5s e c o n d sa t5 6 ° C ,1m i n
at 72°C. The amplified products were separated on 2%
agarose gels and analyzed using Gel-Pro analyzer soft-
ware (version 3.0; Media Cybernetics, inc.). The density
of each band was measured by densitometry. The values
AT1R/b-actin and AT2R/b-actin were used to express
the levels of AT1R and AT2R mRNA, respectively.
Western blot analysis
The aortic tissues from four or five rats and treated
VSMCs in each experimental group were analyzed in the
western blots. Isolation of total protein, electrophoresis,
and blotting were performed as previously described [20].
Briefly, equal amounts of membrane proteins (50 μg) from
various groups were separated by 10% SDS-PAGE and
transferred to polyvinylidene fluoride membrane (Pall Life
Science, USA). After incubation in blocking solution (10%
Bovine Serum Albumin) for 60 min, the membranes were
incubated in a buffer containing 2.0 g/mL specific goat
anti-rat AT1Ro rA T 2R polyclonal antibody (1:1,000
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body (1:8,000 dilution; Sigma). HRP-conjugated donkey
anti-goat polyclonal antibody (Pierce Biotechnology, USA)
was used as secondary antibody at 1:10,000 dilution. Che-
miluminescent luminol reagent (sc - 2048, Santa Cruz Bio-
technology, inc.) was used to detect the signal that was
recorded on X-ray film. All western blot experiments were
repeated at least three times with different aortic prepara-
tions. Band intensity was measured using Gel-Pro analyzer
software.
Statistical analysis
Statistical analysis was performed by using SPSS 12.0.1
software (SPSS, Inc., Chicago, IL). All data are expressed
as mean ± SD. The differences between all measured
values were assessed by one-way ANOVA followed by
post-hoc analysis with Tukey multiple comparison test.
Av a l u eo fp < 0.05 was considered statistically significant.
Results
Angiotensin II in plasma and in aortic tissues
Plasma angiotensin II concentrations showed no signifi-
cant differences between the groups. Angiotensin II in
aortic tissues was substantially increased in the rats on a
cholesterol-rich diet plus methylthiouracil (P <0 . 0 1 ) .
Rosiglitazone markedly attenuated this increase in
angiotensin II in aortic tissues (P < 0.01) (Table 1).
Lipid profiles
Taking the cholesterol-rich diet plus methylthiouracil
for 6 months caused hypercholesterolemia, including
increase in serum TC, TG, and LDL-C levels in 2 sub-
groups. However, the increases in TC, LDL-C, and TG
levels were significantly suppressed in the rats on rosi-
glitazone treatment, as compared to those in the Cho
group (P < 0.01) (Table 1).
Evaluation of atherosclerotic lesions
After 6 months in the Cho group, proximal aortas
showed early arterial changes characterized by an accu-
mulation of lipids in intima, VSMC proliferation, and
migration toward intima, but no typical atherosclerotic
plaques were found in any section of the proximal aorta.
These pathological changes were barely visible in the
rosiglitazone-treated rats (Figure 1).
Evaluation of VSMC proliferation
Cultured VSMCs showed fusiform shape, valley-like fea-
ture under phase contrast microscope (Figure 2A).
Unique cordlike myofilaments and macula densa were
observed in cytoplasm under transmission electron
microscope (Figures 2B and 2C). Myofilament structure
of distribution along longitudinal axis were clearly visi-
ble, while cell nucleus were not stained (Figure 2D).
The mean absorbance in the VSMCs treated with
1 μmol/L ANG II for 6 h was significantly high as com-
pared with that of the Con group (P < 0.01). The absor-
bance were markedly reduced in the VSMCs treated
with different concentration rosiglitazones (20, 30, 50)
μm o l / Lf o r1 2ho rw i t h3 0μmol/L rosiglitazone for (6,
12, 24) h, reaching a minimum in 50 μmol/L rosiglita-
zone for 12 h or 30 μmol/L rosiglitazone for 24 h
respectively (P < 0.05, 0.01) (Tables 2 and 3).
Protein and mRNA expression of angiotensin II receptors
in aortic tissues
Immunohistochemical staining of the proximal aortic
sections revealed the presence of AT1R and AT2R in the
endothelial layer and the media in all rats (Figure 3).
AT1R and AT2R showed the lower level of expression in
the rats that were fed the regular diet. However, immu-
noreactivity to both AT1Ra n dA T 2R was clearly visible
on the endothelial layer, media, and adventitial tissue in
rats on the cholesterol-rich diet plus methylthiouracil,
and protein expression of AT1R and AT2R was dramati-
cally increased compared to rats on a regular diet
(Figure 4) (P < 0.01). In addition, the rats on the choles-
terol-rich diet plus methylthiouracil had much greater
levels of AT1R mRNA and 3-fold higher AT2Rm R N A
levels than the rats on the regular diet (Figure 5) (P <
0.01). Compared with the Cho group, rosiglitazone sig-
nificantly attenuated AT1R immunoreactivity, down-
regulated protein and mRNA expression of AT1Ri nt h e
aorta (P < 0.01), while further up-regulated protein and
mRNA expression of AT2R( P < 0.01) (Figures 4 and 5).
Protein and mRNA expression of angiotensin II receptors
in VSMCs
In vitro, the protein and mRNA expression of AT1Rw a s
markedly up-regulated in the VSMCs on ANG II treatment
(P < 0.01), in contrast, protein and mRNA expression of
Table 1 Comparisons of serum lipids, ANG II level in plasma and aortic tissues (mean ± SD)
groups n ANG II in plasma
(pg/ml)
ANG II in aortic tissue
(ng/mg)
TG mmol/L TC mmol/L LDL-C mmol/L
Con 8 142.61 ± 42.78 2.45 ± 0.10 0.79 ± 0.17 1.53 ± 0.23 0.31 ± 0.22
Cho 10 139.16 ± 64.46 4.72 ± 0.91 * 2.15 ± 0.30 * 4.66 ± 0.56 * 1.93 ± 0.21 *
Ros 10 173.97 ± 97.52 3.05 ± 0.39
‡ 0.58 ± 0.13
‡ 2.57 ± 0.27
‡ 1.20 ± 0.12
‡
Con: regular diet group; Cho: cholesterol-rich diet plus methylthiouracil group; Ros: the group with cholesterol-rich diet plus methylthiouracil and rosiglitazone.
*P < 0.01 versus Con group;
‡P < 0.01 versus Cho group.
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Compared with the ANG II group, with increasing concen-
trations of rosiglitazone (20, 30, 50) μmol/L and increasing
time (6, 12, 24) h treated with 30 μmol/L rosiglitazone, the
protein and mRNA expression of AT1R in the VSMCs was
markedly attenuated (P < 0.05, 0.01). However, protein and
mRNA expression of AT2R was significantly increased (P <
0 . 0 1 )( F i g u r e s6a n d7 ) .
Discussion
Vasculoprotective effects of PPARg ligand agonists
In the present study, early arterial changes characterized
by an accumulation of lipids in intima, VSMC prolifera-
tion and migration toward intima were clearly visible in
the rats given a high-cholesterol diet plus methylthiouracil
for 6 months, although no typical atherosclerotic plaques
were observed. The reason that typical atherosclerosis did
Figure 1 Representative slides of hematoxylin-eosin staining of proximal aortic tissues.C o n :r e g u l a rd i e tg r o u p( 2 0 0× ) ,s h o w i n g
integrated endothelial cell layer and regular arrangement of smooth muscle cells; Cho-a: cholesterol-rich diet plus methylthiouracil (80 mg/Kg/
day) group (200 ×); Cho-b: cholesterol-rich diet plus methylthiouracil group (400 ×), showing smooth muscle cell proliferation, migration toward
intima (broken arrow), and lipid deposition (solid arrow); Ros: cholesterol-rich diet plus methylthiouracil and rosiglitazone treatment (200 ×).
Smooth muscle cell proliferation and lipid deposition were barely observed in the Ros group.
Figure 2 In vitro cultured VSMC features. Cultured VSMCs seen under in phase contrast microscope, were spindle or fusiform shape, showing
valley-like feature (2A, 10×20); Unique cordlike filaments and macula densa in cytoplasm were observed under transmission electron microscope
(2B and 2C, 20×10
3); Immunocytochemical staining of VSMC a-actin clearly showed brown myofilaments of distribution along cell longitudinal
axis. Cell nucleus were not stained (2D, 10×40).
Ren et al. Cardiovascular Diabetology 2011, 10:10
http://www.cardiab.com/content/10/1/10
Page 5 of 12not develop may be associated with the characteristics
of lipid metabolism in the rat per se.T h u s ,i ti sn o t
easy to produce typical atherosclerosis in rats fed a high-
cholesterol diet in the short term, as compared to mice
with gene defects or to other animals, such as the rabbit,
dog, and monkey. Even so, early arterial changes charac-
terized by an accumulation of lipids, VSMC proliferation
and migration toward intima seen in rats on the choles-
terol-rich diet plus methylthiouracil were barely observed
in the rats treated on a long-term basis with rosiglitazone,
which suggested that PPARg agonists can inhibit athero-
sclerotic lesions evoked by cholesterol-rich diet and can
exert vascular protective effects. Although the amount of
animal was small in the current study, this limitation did
not affect our observations regarding vascular protective
actions of rosiglitazone. Recent study has also demon-
s t r a t e dt h a tP P A R g activation prevented hypertensive
remodeling of cerebral arteries and capillary rarefaction as
well as improving vascular function without affecting
blood pressure [21]. In addition, a common feature of
these conditions including cardiovascular diseases, hyper-
tension, dyslipidemia and type 2 diabetes is insulin resis-
tance, which is thought to play a pathogenic role.
However, rosiglitazone may improve insulin resistance
through inhibiting inflammation of adipose tissue, skeletal
muscle and immunologic cells [22,23]. In Zucker diabetic
fatty (ZDF) rats, rosiglitazone treatment for 3 weeks
restored the endothelial function and adrenergic
vasoconstriction, but did not improve the mechanical
properties of blood vessel [24]. Although these studies
have clearly indicated vasculoprotective effects of PPARg
agonists, the conclusion derived from animal studies in
general can not automatically extrapolated to human or
clinical studies. However, recently results from meta-ana-
lysis studies suggested that rosiglitazone use may be asso-
ciated with an increase in the risk of myocardial infarction
from cardiovascular causes [25,26]. These observations
raised questions on the cardiovascular safety of rosiglita-
zone in the treatment of type 2 diabetes. In fact, the
increase in absolute cardiovascular risk after rosiglitazone
treatment was very small in these studies on low-risk
patients, such as DREAM and ADOPT [27,28]. In the
Rosiglitazone Evaluated for Cardiac Outcomes and Regu-
lation of glycemia in Diabetes (RECORD) study, safety
analysis suggested nonsignificant changes in cardiovascu-
lar morbidity and mortality after rosiglitazone treatment
[29]. Furthermore, the results from meta-analyses on pio-
glitazone and the PROactive (PROspective pioglitAzone
Clinical Trial In macroVascular Events) study revealed sig-
nificant benefits regarding the composite of death, myo-
cardial infarction or stroke. Therefore, the place of TZDs
in diabetes treatment strategies still needs further
evaluation.
Moreover, VSMCs migration to subintimal space and
abnormal proliferation is one of the pathological bases of
atherosclerosis. It has been reported that PPARg agonists
inhibit growth factor-induced proliferation and migration
of VSMCs [30,31]. PPARg agonists have also been
demonstrated to inhibit cytokine-mediated endothelial
cell proliferation and endothelin-1(ET-1) secretion from
vascular endothelial cells. The findings of the current
study indicated rosiglitazo n em a r k e d l ya t t e n u a t e dA N G
II- induced VSMC proliferation partially through down-
regulating AT1R expression, and up-regulating AT2R
expression. The effects of PPARg ligand agonists on
VSMCs and vascular endothelial cells are thought to be
beneficial in preventing the process of atherosclerosis.
Therefore, these results have potentially important impli-
cations for optimization of clinical medicine treatments.
Improvement of lipid profiles by the PPARg agonist
There is considerable evidence that hypercholesterole-
mia causes endothelial dysfunction, a prerequisite for
atherosclerosis, in conduit vessels and small arteries.
C u r r e n t l ya v a i l a b l ed a t ai n d i c a t et h a tP P A R g agonists
improve atherosclerosis by ameliorating systemic meta-
bolic risk factors for atherogenesis and inflammatory
events [1,32]. The vasculoprotective actions of rosiglita-
zone can be explained partially by its metabolic regula-
tory effects in the present study. Rosiglitazone
significantly reduced serum TC, TG, and LDL-C
induced by a cholesterol-rich diet plus methylthiouracil.
Table 2 Comparisons of absorbance among groups
treated with different concentration rosiglitazones for 12
h (mean ± SD)
groups wells Absorbance
control 3 0.25 ± 0.01
ANG II 3 0.51 ± 0.02 *
ANG II + 20 μmol/L Ros 3 0.48 ± 0.02
†
ANG II + 30 μmol/L Ros 3 0.43 ± 0.02
‡
ANG II + 50 μmol/L Ros 3 0.32 ± 0.01
‡
*P < 0.01 versus control group;
†P < 0.05 versus ANG II group,
‡P < 0.01
versus ANG II group. Comparisons of among different concentration groups
P < 0.05 or P < 0.01.
Table 3 Comparisons of absorbance among groups
treated with 30 μmol/L rosiglitazone for (6, 12, 24) h
(mean ± SD)
groups wells Absorbance
control 3 0.23 ± 0.01
ANG II 6 h 3 0.52 ± 0.02*
ANG II + 30 μmol/L Ros 6 h 3 0.47 ± 0.02
‡
12 h 3 0.44 ± 0.02
‡ #
24 h 3 0.36 ± 0.03
‡ ##
*P < 0.01 versus control group;
†P < 0.01 versus ANG II group; In rosiglitazone
treatment groups,
#P < 0.05 versus previous point in time,
##P < 0.01 versus
previous point in time.
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Previous studies have demonstrated that PPARg ligand
agonists inhibit atherosclerotic progression through dif-
ferent molecular mechanisms in humans and animals
[33-35]. However, little is known about modulation of
RAS components by PPARg agonists in vasculoprotec-
tion. In addition to its pro-hypertensive effects, angio-
tensin II possesses inflammatory and oxidative effects,
and stimulates vascular smooth muscle cell proliferation
and migration, which are involved in evolution of ather-
osclerosis and restenosis [36-38]. PPARg agonists can
inhibit these effects of ANG II by suppression of the
ANG II-induced signaling pathway, which suggests that
PPARg agonists have beneficial effects against athero-
sclerosis and restenosis [39-41]. In the present study, we
demonstrated that the reduction of ANG II concentra-
tion in the aortic tissues mediated vascular protection of
rosiglitazone. The regulatory mechanism concerning
ANG II levels in local tissues is still poorly known. It
was speculated that the decrease in ANG II levels in
aorta may be associated with the suppression of rosigli-
tazone on angiotensinogen and angiotensin- converting
enzyme.
Most of the physiological effects of ANG II, such as reg-
ulation of blood pressure and fluid homeostasis, have been
attributed to AT1R activation. Several studies have also
highlighted the important role of AT1R in the atherogenic
process [15,42,43]. However, the AT2R is gaining attention
as an opponent to AT1R by its counter-regulatory protec-
tive roles in the cardiovascular system, e.g. angiotensin
type 2 receptor-mediated vasodilation and anti-prolifera-
tion [44-47]. Recent studies have also demonstrated the
anti- atherosclerotic effects of AT2R [48,49]. In our study,
PPARg agonist rosiglitazone markedly suppressed increase
in AT1R expression in aortic tissues in the hypercholester-
olemic rats. In vitro, rosiglitazone significantly attenuated
ANG II-induced increase in AT1R expression in a concen-
tration-dependent and a time-dependent manner. How-
ever, its effect on AT2R expression was different, with
rosiglitazone further up-regulating AT2Re x p r e s s i o ni nt h e
Figure 3 Immunohistochemical staining of protein expression of angiotensin II type 1 receptor (AT1R) and angiotensin II type 2
receptor (AT2R) in aortic tissues. A and F: the negative controls of AT1R and AT2R for the immunohistochemistry, respectively, showing no
positive staining. B and G: the regular diet group; C and H: the cholesterol-rich diet plus methylthiouracil (80 mg/Kg/day) group; D and I: group
with cholesterol-rich diet plus methylthiouracil and rosiglitazone treatment. Rosiglitazone treatment markedly attenuated AT1R immunoreactivity
induced by the cholesterol-rich diet plus methylthiouracil (D), while increased AT2R immunoreactivity (I). (Magnification: 400×).
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Representative blots from aortic samples in each group are shown at the top. The bar graph shows protein expression of AT1Ro rA T 2R relative
to internal control ß-actin (45 kDa) from 4 separate experiments in each group. Con: the regular diet group; Cho: the cholesterol-rich diet plus
methylthiouracil group; Ros: the group on cholesterol-rich diet plus methylthiouracil and rosiglitazone treatment. Note that rosiglitazone
treatment led to the marked reduction in protein expression of AT1R, while further increase in protein expression of AT2R compared with the
Cho group. *P < 0.01 versus Con group;
‡P < 0.01 versus Cho group.
Figure 5 mRNA expression of angiotensin II type 1 receptor (C: AT1R, 352-bp fragment) and type 2 receptor (D: AT2R, 418-bp
fragment) in aortic tissues. Representative samples of AT1R and AT2R mRNA from aortic samples in each group are shown at the top. The bar
graph shows mRNA expression of AT1Ro rA T 2R relative to internal control ß-actin (232-bp fragment) from 4 replicate experiments in each group.
Con: the regular diet group; Cho: the cholesterol-rich diet plus methylthiouracil group; Ros: the group on cholesterol-rich diet plus
methylthiouracil and rosiglitazone treatment. Note that the increase in AT1R mRNA caused by the cholesterol-rich diet plus methylthiouracil was
markedly suppressed by rosiglitazone treatment (P < 0.01). However, mRNA expression of AT2R was further increased (P < 0.01). *P < 0.01 versus
Con group;
‡P < 0.01 versus Cho group.
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Page 8 of 12aortic tissues, and suppressing ANG II-induced decrease
in AT2R expression in a concentration-dependent and a
time-dependent fashion. Based on these findings, the
beneficial effects of PPARg agonists on vessels are
mediated at least partially by the reduction in local tissue
angiotensin II, attenuation of AT1Re x p r e s s i o na n d
increase in AT2R expression although the exact mechan-
ism of PPARg agonist-mediated regulation of RAS com-
ponents is still unclear. It has been reported that PPARg
agonist-mediated modulation of AT1R has been
associated with suppression of the activity of the AT1R
promoter [50].
In conclusion, the present study demonstrated that
PPARg agonist rosiglitazone attenuated ANG II-induced
VSMC proliferation in vitro and early atherosclerotic
formation evoked by cholesterol-rich diet in vivo. These
vasculoprotective effects of rosiglitazone were mediated
at least partially by the improvement of lipid profiles,
reduction in local tissue ANG II concentration, down-
regulation of AT1R expression and up-regulation of
AT2R expression both at the mRNA and protein levels.
However, further studies are necessary to elucidate the
molecular mechanism of regulation of RAS components
by PPARg agonists in vascular protection.
Figure 6 Effects of rosiglitazone treatment on protein expression of ANG II-induced angiotensin II type 1 receptor (A: AT1R, 43 kDa)
and type 2 receptor (B: AT2R, 44 kDa) in vitro cultured VSMCs. (C): VSMCs were pretreated with 1 μmol/L ANG II for 6 h and subsequently
treated for 12 h as follows: Con, ANG II, ANG II plus different concentration rosiglitazones (20, 30, 50) μmol/L; (D): VSMCs were pretreated with
1 μmol/L ANG II for 6 h and subsequently treated with 30 μmol/L rosiglitazone for (6, 12, 24) h, respectively. Representative blots from each
experimental group are shown at the top. The bar graph shows protein expression of AT1Ro rA T 2R relative to internal control ß-actin (45 kDa)
from 3 separate experiments in each group. *P < 0.01 versus Con group, ** P < 0.05 versus Con group;
‡P < 0.01 versus ANG II.
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